Inovio Pharmaceuticals Stock Earnings Reports

Inovio is focused on advancing its lead candidate, INO-3107, through the FDA review process with a target PDUFA date of October 30, 2026. The BLA was accepted under the accelerated approval pathway and the FDA completed its mid-cycle review with no new significant issues; an informal meeting to discuss eligibility for accelerated approval is expected to be scheduled. Inovio believes INO-3107 meets accelerated-approval criteria based on Phase I/II efficacy (large reductions in surgery rates), an improved safety profile (no requirement for surgery to maintain minimal residual disease during dosing), and a differentiated mechanism of action that may treat patients not helped by the currently approved gorilla adenoviral product. Commercial preparedness is underway: Inovio plans to self-manage commercialization supported by a contract sales organization and has engaged logistics, specialty pharmacy, distributor and patient hub partners; the company expects to be a “fast-following” second entrant if approved and is incorporating learnings from the competitor’s launch. Partnerships continue to advance other programs (e.g., collaboration with Akeso and Dana-Farber for GBM; DPROT preclinical work in hemophilia A, Fabry disease, hypophosphatasia). Financially, Inovio ended Q1 2026 with $37.7M cash and completed an April 2026 public offering that added about $16M net proceeds, extending runway into Q1 2027; estimated operational net cash burn is roughly $18M for Q2 2026. Q1 operating expenses were $21.9M (down 13% year-over-year) and net loss was $19.7M. Key risks for investors include the FDA’s ultimate determination on accelerated approval eligibility, the timing and outcome of the informal meeting and feedback on the confirmatory trial design, potential need for additional capital beyond current runway, and competitive dynamics in RRP.